GlaxoSmithKline [GLAXO] vs Marksans Pharma [MARKSANS] Detailed Stock Comparison

GlaxoSmithKline

NSE

Marksans Pharma

NSE

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: GlaxoSmithKline wins in 13 metrics, Marksans Pharma wins in 6 metrics, with 0 ties. GlaxoSmithKline appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric	GlaxoSmithKline	Marksans Pharma	Better
P/E Ratio (TTM)	50.31	26.68	Marksans Pharma
Price-to-Book Ratio	24.56	4.15	Marksans Pharma
Debt-to-Equity Ratio	0.51	12.93	GlaxoSmithKline
PEG Ratio	48.86	N/A	N/A
EV/EBITDA	38.72	19.74	Marksans Pharma
Profit Margin (TTM)	25.41%	14.51%	GlaxoSmithKline
Operating Margin (TTM)	29.27%	14.54%	GlaxoSmithKline
EBITDA Margin (TTM)	29.27%	14.54%	GlaxoSmithKline
Return on Equity	47.54%	16.73%	GlaxoSmithKline
Return on Assets (TTM)	22.58%	9.40%	GlaxoSmithKline
Free Cash Flow (TTM)	$12.65B	$337.45M	GlaxoSmithKline
Dividend Yield	1.65%	0.62%	GlaxoSmithKline
1-Year Return	-6.38%	10.63%	Marksans Pharma
Price-to-Sales Ratio (TTM)	12.81	3.90	Marksans Pharma
Enterprise Value	$454.33B	$98.94B	GlaxoSmithKline
EV/Revenue Ratio	12.15	3.77	Marksans Pharma
Gross Profit Margin (TTM)	64.27%	54.09%	GlaxoSmithKline
Revenue per Share (TTM)	$221	$58	GlaxoSmithKline
Earnings per Share (Diluted)	$56.23	$8.46	GlaxoSmithKline
Beta (Stock Volatility)	0.06	1.26	GlaxoSmithKline

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

GlaxoSmithKline vs Marksans Pharma Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
GlaxoSmithKline	-1.32%	-15.34%	-18.49%	-6.07%	21.26%	19.95%
Marksans Pharma	-1.57%	-5.76%	-16.72%	-4.96%	-21.46%	-29.64%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
GlaxoSmithKline	-6.38%	85.69%	76.49%	-27.19%	36.57%	487.72%
Marksans Pharma	10.63%	332.80%	340.76%	100.42%	5,227.16%	682.84%

Performance Comparison

This comparison requires JavaScript for dynamic charts and real-time data. For complete performance analysis, visit the individual stock overview pages:

GlaxoSmithKline (GLAXO): View Full Stock Overview

Marksans Pharma (MARKSANS): View Full Stock Overview

The individual stock overview pages contain detailed performance metrics, historical charts, financial data, and comparison tools that work without JavaScript.

Key Performance Metrics Available:

Daily, weekly, monthly, and yearly returns
52-week high and low prices
Market capitalization and valuation ratios
Financial health and profitability metrics
Dividend history and yield information

Performance & Financial Health Analysis: GlaxoSmithKline vs Marksans Pharma

Metric	GLAXO	MARKSANS
Market Information
Market Cap i	₹479.22B	₹102.29B
Market Cap Category	Large cap	Mid cap
10 Day Avg. Volume i	108,705	2,144,841
90 Day Avg. Volume i	102,776	1,321,174
Last Close	₹2,642.20	₹210.99
52 Week Range	₹1,921.00 - ₹3,515.70	₹171.00 - ₹358.70
% from 52W High	-24.85%	-41.18%
All-Time High	₹3,872.00 (Mar 28, 2016)	₹358.70 (Dec 02, 2024)
% from All-Time High	-31.76%	-41.18%
Growth Metrics
Quarterly Revenue Growth	-0.01%	0.27%
Quarterly Earnings Growth	0.12%	0.16%
Financial Health
Profit Margin (TTM) i	0.25%	0.15%
Operating Margin (TTM) i	0.29%	0.15%
Return on Equity (TTM) i	0.48%	0.17%
Debt to Equity (MRQ) i	0.51	12.93
Cash & Liquidity
Book Value per Share (MRQ)	₹115.19	₹54.44
Cash per Share (MRQ)	₹147.46	₹15.58
Operating Cash Flow (TTM) i	₹12.73B	₹2.07B
Levered Free Cash Flow (TTM) i	₹9.28B	₹-725,402,496
Dividends
Last 12-Month Dividend Yield i	1.65%	0.62%
Last 12-Month Dividend i	₹54.00	₹1.40

Valuation & Enterprise Metrics Analysis: GlaxoSmithKline vs Marksans Pharma

Metric	GLAXO	MARKSANS
Price Ratios
P/E Ratio (TTM) i	50.31	26.68
Forward P/E i	48.86	15.91
PEG Ratio i	48.86	N/A
Price to Sales (TTM) i	12.81	3.90
Price to Book (MRQ) i	24.56	4.15
Market Capitalization
Market Capitalization i	₹479.22B	₹102.29B
Enterprise Value i	₹454.33B	₹98.94B
Enterprise Value Metrics
Enterprise to Revenue i	12.15	3.77
Enterprise to EBITDA i	38.72	19.74
Risk & Other Metrics
Beta i	0.06	1.26
Book Value per Share (MRQ) i	₹115.19	₹54.44

Financial Statements Comparison: GlaxoSmithKline vs Marksans Pharma

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	GLAXO	MARKSANS
Revenue/Sales i	₹8.05B	₹7.08B
Cost of Goods Sold i	₹2.88B	₹3.25B
Gross Profit i	₹5.17B	₹3.83B
Research & Development i	N/A	N/A
Operating Income (EBIT) i	₹2.36B	₹1.03B
EBITDA i	₹2.95B	₹1.42B
Pre-Tax Income i	₹2.79B	₹1.16B
Income Tax i	₹739.70M	₹253.68M
Net Income (Profit) i	₹2.05B	₹907.25M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	GLAXO	MARKSANS
Cash & Equivalents i	₹5.39B	₹4.96B
Total Current Assets i	₹34.10B	₹22.04B
Total Current Liabilities i	₹19.05B	₹4.77B
Long-Term Debt i	₹24.92M	₹2.63B
Total Shareholders Equity i	₹19.51B	₹24.89B
Retained Earnings i	₹10.59B	N/A
Property, Plant & Equipment i	₹2.70B	₹8.86B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	GLAXO	MARKSANS
Operating Cash Flow i	N/A	N/A
Capital Expenditures i	N/A	N/A
Free Cash Flow i	N/A	N/A
Debt Repayment i	N/A	N/A
Common Stock Repurchase i	N/A	N/A

Short Interest & Institutional Ownership Analysis

Metric	GLAXO	MARKSANS
Shares Short i	N/A	N/A
Short Ratio i	N/A	N/A
Short % of Float i	N/A	N/A
Average Daily Volume (10 Day) i	108,705	2,144,841
Average Daily Volume (90 Day) i	102,776	1,321,174
Shares Outstanding i	169.41M	453.16M
Float Shares i	41.29M	214.46M
% Held by Insiders i	0.76%	0.46%
% Held by Institutions i	0.09%	0.17%

Dividend Analysis & Yield Comparison: GlaxoSmithKline vs Marksans Pharma

Metric	GLAXO	MARKSANS
Last 12-Month Dividend i	₹54.00	₹1.40
Last 12-Month Dividend Yield i	1.65%	0.62%
3-Year Avg Annual Dividend i	₹59.33	₹0.72
3-Year Avg Dividend Yield i	1.86%	0.40%
3-Year Total Dividends i	₹178.00	₹2.15
Ex-Dividend Date	May 30, 2025	Aug 01, 2025

GlaxoSmithKline [GLAXO] vs Marksans Pharma [MARKSANS] Detailed Stock Comparison